Publications

Cheuvart B, Burgess M, Zepp F, Mertsola, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004;23:336-42. [Abstract]

Ackermann D, Chapman S, Leask J. Media coverage of anthrax vaccination refusal by Australian Defence Force personnel. Vaccine 2004;23:411-7. [Abstract]

McIntyre PB, Turnbull FM, Egan A, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004;23:380-5. [Abstract]

Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004;23:132-8. [Abstract]

Beutels P, Viney RC. Comments on the Prosser et al approach to value disease reduction in children [letter] . Pediatrics 2004;114:1375. [Abstract]

Lawrence GL, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Communicable Diseases Intelligence 2004;28:324-38. [Full text]

Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, Van Damme P. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004;22:3546-62. [Abstract]

Lawrence G, Boyd I. Surveillance of adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Communicable Diseases Intelligence 2004;28:490-2. [Full text]

Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004;22:3312-22. [Abstract]

Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Communicable Diseases Intelligence 2004;28:244-8. [Abstract]